Fueling Hope: Aardvark Therapeutics’ $85M Boost Powers Breakthrough PWS Treatment

Aardvark Therapeutics has just hit a major milestone with an exciting $85 million Series C financing round! Led by Decheng Capital, with additional participation from several investors, including PWSA | USA, this funding is set to drive the development of ARD-101, a groundbreaking treatment for hyperphagia in Prader-Willi syndrome patients.

ARD-101 showed promising early trial results and received FDA backing through Orphan Drug Designation and Rare Pediatric Disease Designation. The support from investors and advocacy groups showcases the urgency and excitement surrounding this innovative therapy, offering hope and tangible progress for individuals facing the challenges of PWS.

Get ready for a journey fueled by innovation, collaboration, and unwavering dedication to transforming lives!

Read the full press release announcement at the button below.

Share this!

Scroll to top